Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BioXcel Therapeutics, Inc.

OTC: BTAIQ · Life Sciences · 1 alert · CIK 1720893

Share price
$0.0110Close, Nov 16
Market cap
$344K
Shares outstanding
31.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioXcel Therapeutics, Inc. filings on SEC EDGAR ↗

5:15 PM ET 8-K
Divestiture

BioXcel Therapeutics Divestiture to Teva Pharmaceuticals International GmbH for $57.5M

BioXcel Therapeutics completed the sale of substantially all of its neuroscience assets, including IGALMI and BXCL501, to Teva Pharmaceuticals for $57.5 million in upfront cash. The company is also eligible for up to $67.5 million in development milestones and $20 million in commercial milestones. The sale was conducted under Section 363 of the Bankruptcy Code as part of BioXcel's Chapter 11 proceedings.

Value
$57.5M
Counterparty
Teva Pharmaceuticals International GmbH

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.